A federal nudge to shorten medication assisted treatment is already changing how clinics prescribe, and it has split the recovery field at a moment when overdose deaths were finally falling.
For the first time since the COVID-era overdose crisis turned medications for opioid addiction into a bipartisan consensus, federal health officials have put a thumb on the scale against keeping patients on them long term, and addiction physicians say it is already changing how treatment is delivered.
The signal arrived on April 24, 2026, when the Substance Abuse and Mental Health Services Administration issued two "Dear Colleague" letters signed by its acting leader, Chris Carroll. The first, on medication-assisted treatment for opioid use disorder, described methadone and buprenorphine as part of the path to "long-term recovery and sobriety, self-sufficiency, and thriving, and not as a default sentence to life-long medication use." The companion letter, on harm reduction, told grant recipients that federal dollars should not be used to purchase fentanyl test strips. Both letters are available on SAMHSA's site, with the harm-reduction guidance posted here.
Neither letter directly disputes that methadone and buprenorphine work. But the language, according to STAT News addiction reporter Lev Facher, has been read inside the treatment world as a federal nudge to shorten medication courses, lean on recovery-support services, and discourage the once-routine practice of keeping patients on these drugs for years.
That is a meaningful change. For more than a decade, the medical consensus, built on observational and experimental studies cited in SAMHSA's own materials and in the clinical literature, has been that people on medications for opioid use disorder (MOUD) are more than 50 percent less likely to die of a drug overdose than those not on them, and that longer treatment duration is consistently associated with better outcomes. "Most of the data are six to 12 months," Dr. David Fiellin, director of the Yale Program in Addiction Medicine, told STAT. Evidence past about two years is thinner. Shorter durations, especially when forced, raise the risk of relapse and death.
What makes the SAMHSA letter unusual is what it leans on. The agency's own letter cites the American Society of Addiction Medicine's practice guidelines, which say a patient's decision to decline psychosocial treatment should not, by itself, delay or preclude pharmacotherapy. Read together, the two documents push in opposite directions, and addiction physicians say the letter's framing of "supportive services" as essential puts the weight on clinicians to nudge patients off medication.
"The winds clearly have shifted away from thinking about evidence-based ways of engaging people who use drugs ... and more toward focusing on the punitive and public safety," said Dr. Yngvild Olsen, a former director of SAMHSA's Center for Substance Abuse Treatment, in remarks to STAT. Olsen left the agency in early 2025.
SAMHSA's posture matters because the agency has been without a confirmed director for more than 15 months into the Trump administration. Staffing has fallen from roughly 900 to under half that, and STAT has reported that the agency has cancelled about $1.7 billion in block-grant funding and roughly $350 million in addiction and overdose-prevention grants since January 2025. That is the context in which a single "Dear Colleague" letter, signed by an acting leader, can shift prescribing expectations across the country.
One name in particular has tracked this shift. In October 2025, the Senate confirmed Michael Stuart, a former West Virginia state lawmaker who had co-authored a bill to ban methadone clinics in his state, as HHS general counsel. Stuart was recently reassigned to an unknown HHS role after NOTUS reported that he had traded stock in a major federal contractor. He is no longer in the daily MOUD policy chain, but his appointment, and the ideology behind it, helped set the table for the April letters.
On the legislative side, the policy direction is being carried by a single member. In September 2025, Rep. Erin Houchin, an Indiana Republican, introduced H.R. 5629, which would require daily in-person visits to a methadone clinic in the first months of treatment, reimpose a one-year opioid addiction threshold before a patient can receive methadone, and bar doctors from evaluating patients for methadone or buprenorphine via telehealth. The bill has no co-sponsors and has not had a hearing in the House Energy and Commerce Committee, according to STAT's reporting on the legislation.
In March 2026, a coalition that included ASAM, the American Academy of Family Physicians, and the American College of Academic Addiction Medicine wrote to Houchin warning that, "If enacted as currently drafted, the bill would result in more opioid overdoses." That letter, hosted on ACAAM's site, reads as a near-unanimous pushback from the medical groups that actually run addiction treatment in the United States.
The contrast with the start of the administration is sharp. In February 2025, the Senate confirmed Robert F. Kennedy Jr. as HHS secretary, the first openly in-recovery person to lead the department. That April, at the Rx Summit in Nashville, Kennedy was explicit: "We need Suboxone, we need methadone, we need naltrexone, we need Narcan," he said, as quoted in STAT's analysis. Fourteen months later, the agency under his department is encouraging clinicians to discuss tapering patients off those same drugs at least annually.
This is not a flat Republican reversal. Methadone, buprenorphine, and naltrexone remain the only three drugs approved by the FDA to treat opioid use disorder, and U.S. overdose deaths have dropped below 70,000 a year for the first time since 2019, progress the administration has claimed credit for. A small but persistent wing of the recovery community has long argued that medication is not the only path, and the SAMHSA letter, in a narrow reading, reflects that view. Stephen Taylor, president of ASAM, has been measured in his public comments, telling STAT that the organization is "engaging with federal partners" to ensure national policy reflects evidence-based practice and that patients retain access to MOUD "when clinically appropriate."
"Engaging" is not "endorsing," and the day-to-day effect on treatment is already visible. Methadone is dispensed only at specialized opioid treatment programs, many of which already require multiple early-morning visits a week, frequent drug testing, and counseling. Buprenorphine, sold in part as Suboxone, is an opioid itself and can be hard to discontinue. Sharp cuts in methadone dose can cause severe withdrawal and raise relapse risk. A federal signal telling clinicians to reconsider the length of medication, on top of clinics that are already difficult to get to, lands harder in rural counties, in carceral settings, and on pregnant patients with opioid use disorder, who are typically steered toward medication, not away from it.
The decision-making power is not all in Washington. State Medicaid programs still set reimbursement rules for opioid treatment programs and for buprenorphine prescribers. The DEA continues to control methadone and buprenorphine at the pharmacy level. The courts and the carceral system handle a meaningful share of the country's involuntary MOUD decisions. And individual prescribers still choose, for now, how to talk to patients about staying on medication.
But the federal floor has moved. The April MOUD "Dear Colleague" letter and its harm-reduction companion are not a ban. They are the kind of guidance that shapes insurance coverage, clinic policy, and the conversations clinicians feel comfortable having with patients who are doing well on long-term medication. The patients most at risk of being affected by that shift are the ones least likely to read a federal register notice when it lands.
What to watch: whether HHS names a confirmed SAMHSA director, and whether that person walks back the April 24 letters or doubles down on them; whether H.R. 5629 picks up a co-sponsor or a hearing; whether state Medicaid agencies and private insurers tighten or loosen the rules on multi-year MOUD coverage; and whether the next batch of overdose-death numbers, the first to reflect the April guidance, moves up or down.